中国药物评价2026，Vol.43Issue(2)：133-137,5.
安罗替尼对难治性分化型甲状腺癌VEGF/VEGFR通路及临床获益的影响研究
Effect of Anlotinib on the VEGF/VEGFR Pathway and Clinical Benefits in Refractory Differentiated Thyroid Cancer
摘要
Abstract
Objective:To observe the effect of anlotinib on the VEGF/VEGFR pathway and clinical benefits in patients with refractory differentiated thyroid cancer(DTC).Methods:A prospective study was conducted on 98 patients with refractory DTC who were treated in our hospital from May 2023 to May 2024,and a parallel controlled trial was designed.They were divided into the conventional group and the experimental group using a simple random grouping method,with 49 cases in each group.The conventional group was treated with RAI,while the experimental group was treated with anlotinib combined with RAI.The VEGF/VEGFR pathway proteins,tumor microenvi-ronment,and tumor burden were compared between the two groups of patients.After one year of follow-up after treatment,the prognosis of the two groups of patients was compared.Analyze the correlation between VEGF/VEGFR and clinical indicators.Results:After treat-ment,the relative expression levels of VEGF and VEGFR in the experimental group were(1.66±0.35)and(1.52±0.41),respective-ly,which were lower than those in the conventional group[(2.53±0.39),(2.44±0.57)](P＜0.05).The levels of HIF-1α and CA9 in the experimental group were higher than those in the control group,while the levels of MMP2 and MMP9 were lower than those in the control group(P＜0.05).The ORR and DCR of the experimental group were 79.59％(39/49)and 87.76％(43/49),respective-ly,which were higher than those of the control group[55.10％(27/49),61.22％(30/49)](P＜0.05).As of the end of follow-up,the mPFS and mOS of the experimental group were higher than those of the control group(P＜0.05).VEGF and VEGFR are negatively correlated with HIF-1 α and CA9,and positively correlated with MMP2 and MMP9(r=-0.751,-0.822,0.745,0.816,-0.733,-0.806,0.814,0.795,P＜0.05).Conclusion:Anlotinib improves the tumor microenvironment and reduces tumor burden in patients with refractory DTC,and has a positive impact on enhancing short-term survival benefits.Its mechanism of action may be related to the inhibition of VEGF/VEGFR pathway activity.关键词
难治性分化型甲状腺癌/放射性碘治疗/安罗替尼/血管内皮生长因子/血管内皮生长因子受体/临床获益Key words
Refractory differentiated thyroid cancer/Radioactive iodine therapy/Anlotinib/Vascular endothelial growth factor/vas-cular endothelial growth factor receptor/Clinical benefit分类
医药卫生引用本文复制引用
杨璐,吴东婉,陈笑笑..安罗替尼对难治性分化型甲状腺癌VEGF/VEGFR通路及临床获益的影响研究[J].中国药物评价,2026,43(2):133-137,5.基金项目
河南省医学科技攻关项目(LHGJ2021001321) （LHGJ2021001321）
